Acute Lung Injury - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 105 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Lung Injury - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H2 2015', provides an overview of the Acute Lung Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Lung Injury Overview 10
Therapeutics Development 11
Pipeline Products for Acute Lung Injury - Overview 11
Pipeline Products for Acute Lung Injury - Comparative Analysis 12
Acute Lung Injury - Therapeutics under Development by Companies 13
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15
Acute Lung Injury - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Acute Lung Injury - Products under Development by Companies 18
Acute Lung Injury - Products under Investigation by Universities/Institutes 20
Acute Lung Injury - Companies Involved in Therapeutics Development 21
Altor BioScience Corporation 21
Apeptico Forschung und Entwicklung GmbH 22
Bayer AG 23
BioMarck Pharmaceuticals, Ltd. 24
Carolus Therapeutics, Inc. 25
CompleGen, Inc. 26
FirstString Research, Inc. 27
GlaxoSmithKline Plc 28
Histocell S.L. 29
Navigen Pharmaceuticals, Inc. 30
Noxxon Pharma AG 31
Quark Pharmaceuticals, Inc. 32
S-Evans Biosciences, Inc. 33
Silence Therapeutics Plc 34
Stemedica Cell Technologies, Inc. 35
Xiber Science GmbH 36
Acute Lung Injury - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ALT-836 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Atu-111 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Atu-112 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BAY-858501 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BC-1215 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BIO-10901 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CGX-1037 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CMB-200 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CT-2009 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GSK-2586881 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GSK-2862277 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HC-016 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
LTI-02 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MG-53 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NAV-2729 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NOXD-19 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
P- BEFizumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
QPLI-2 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
S-1229 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
solnatide - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Stem Cell Therapy for Acute Lung Injury - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Stromal Cell Therapy for Acute Lung Injury - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TXA-302 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Xib-1301 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Acute Lung Injury - Recent Pipeline Updates 93
Acute Lung Injury - Dormant Projects 98
Acute Lung Injury - Discontinued Products 99
Acute Lung Injury - Product Development Milestones 100
Featured News & Press Releases 100
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 100
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 100
Jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For CT-2009 Supporting Development In Acute Lung Injury 101
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 102
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 102
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 104
Disclaimer 105

List of Tables

Number of Products under Development for Acute Lung Injury, H2 2015 11
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Acute Lung Injury - Pipeline by Altor BioScience Corporation, H2 2015 21
Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2015 22
Acute Lung Injury - Pipeline by Bayer AG, H2 2015 23
Acute Lung Injury - Pipeline by BioMarck Pharmaceuticals, Ltd., H2 2015 24
Acute Lung Injury - Pipeline by Carolus Therapeutics, Inc., H2 2015 25
Acute Lung Injury - Pipeline by CompleGen, Inc., H2 2015 26
Acute Lung Injury - Pipeline by FirstString Research, Inc., H2 2015 27
Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H2 2015 28
Acute Lung Injury - Pipeline by Histocell S.L., H2 2015 29
Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 30
Acute Lung Injury - Pipeline by Noxxon Pharma AG, H2 2015 31
Acute Lung Injury - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 32
Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H2 2015 33
Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H2 2015 34
Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2015 35
Acute Lung Injury - Pipeline by Xiber Science GmbH, H2 2015 36
Assessment by Monotherapy Products, H2 2015 37
Number of Products by Stage and Target, H2 2015 39
Number of Products by Stage and Mechanism of Action, H2 2015 41
Number of Products by Stage and Route of Administration, H2 2015 43
Number of Products by Stage and Molecule Type, H2 2015 45
Acute Lung Injury Therapeutics - Recent Pipeline Updates, H2 2015 93
Acute Lung Injury - Dormant Projects, H2 2015 98
Acute Lung Injury - Discontinued Products, H2 2015 99